Citations

Clear

2303 citation(s) found for "Yu, Edward".

Abstract 4361481: Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy: A Meta-Analysis with Reconstructed Time-to-Event and Trial Sequential Analysis
Elbenawi, Hossam , Elsalmouny, Youmna, Mohamed, Kareem , Wagdy, Mohamed, Hamed, Belal, Thakurathi, Priyesh , Kalaiger, Abdul M., Ibrahim, Ahmed M. , Eisa, Mahmoud , Ibrahim, Ramzi , Zaaya, Morad, Almaadawy, Omar , Quelal, Karol , Lee, Justin Z. , Siontis, Konstantinos C. , Munoz, Freddy Del‐Carpio , DeSimone, Christopher P., Deshmukh, Abhishek , Agarwal, Siddharth , Agarwal, Siddharth , Hashim, Ahmed , Agarwal, Siddharth, Wagdy, Mohamed , Hamed, Belal, Al‐Shammari, Ali Saad , Ibrahim, Ramzi , Tan, Min Choon , Asad, Zain Ul Abideen , Desimone, Christopher, Deshmukh, Abhishek

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4361481 Get It

Background: Ventricular tachycardia (VT) is a major contributor to death among ischemic heart disease (IHD) patients. In this systematic review and meta-analysis, we evaluate the efficacy of catheter ablation in patients with ischemic cardiomyopathy. Methods: We conducted a meta-analysis by searching the electronic database up to April 2025. Seven studies, including 1192 patients, were identified. A random-effect model was used to estimate pooled risk ratios (RRs) and 95% confidence intervals (CIs). Trial sequential analysis was conducted to assess sample size adequacy. Results: Among Ischemic heart disease patients with ICDs, VT ablation was associated with a significant reduction in ICD shocks (RR = 0.50, 95% CI [0.34–0.74]), a trend toward reduced VT storm (RR = 0.64, 95% CI [0.40–1.04], p = 0.07), and lower rates of cardiovascular hospitalization (RR = 0.73, 95% CI [0.53–1.01], p = 0.06) compared to ICD alone. However, no significant differences were observed when compared to patients receiving ICD plus antiarrhythmic drugs (AADs). Additionally, VT ablation showed no significant impact on mortality or VT/VF recurrence compared to either ICD alone or ICD with AADs. Trial Sequential Analysis provided conclusive evidence for VT/VF recurrence outcomes, while further data are required for other outcomes. Conclusion: Among ischemic heart disease patients with ICD, VT ablation reduces ICD shocks, VT storm, and cardiovascular hospitalizations compared to ICD-only, but offers no significant advantage over ICD combined with antiarrhythmic drugs. VT ablation does not impact mortality or the recurrence of VT/VF. Trial Sequential Analysis confirmed conclusive evidence for VT/VF recurrence, while additional data is needed for other outcomes.
Using large language models to automate summarization of CT simulation orders in radiation oncology
Cao, Meiyun, Hu, S.X. , Sharp, Jason, Clouser, Edward , Lam, Louis, Ding, Xiaoning, Toesca, Diego Santos, Raulston, Brianne C, Lindholm, Wendy S., Patel, Samir H. , Vora, Sujay A., Wang, P. , Clouser, Edward Lee , Lam, Linda L, Wang, Peilong , Liu, Wei , Toesca, Diego A.S. , Hu, Shaw, Sharp, Jason, Holmes, Jason , Liu, Wei

Mayo Clinic

Journal of Applied Clinical Medical Physics | October 28, 2025 | Volume: 26 | Issue: 11 | Pages: No page available

10.1002/acm2.70310 | PMID 41144781 Get It

Abstract Background In the current clinical workflow of radiation oncology, therapists manually summarize the physician‐issued Computed Tomography (CT) simulation orders to prepare patients' CT simulations. This process increases the workload, introduces variability in documentation quality, and is prone to human errors. Purpose This study aims to address these challenges using a large language model (LLM) to automate the generation of summaries from the CT simulation orders and evaluate its performance. Methods A total of 607 CT simulation orders were collected from the Aria database at our institution. A locally hosted LLaMa 3.1 405B model, accessed via the Application Programming Interface (API) service, was used to extract keywords from the CT simulation orders and generate summaries. The downloaded CT simulation orders were categorized into seven groups based on treatment modalities and disease sites. For each group, a customized instruction prompt was developed collaboratively with therapists to guide the LLaMa 3.1 405B model in generating summaries. The ground truth for the corresponding summaries was manually derived by carefully reviewing each CT simulation order and subsequently verified by therapists. The accuracy of the LLM‐generated summaries was evaluated by therapists using the ground truth. Results Over 98% of the LLM‐generated summaries aligned with the ground truth in terms of accuracy. Our evaluations showed an improved consistency in format and enhanced readability from the LLM‐generated summaries compared to the corresponding therapist‐generated summaries. This automated approach demonstrated consistent performance across all groups, regardless of treatment modality or disease site. Conclusions This study demonstrated the high precision and consistency of the LLaMa 3.1 405B model in extracting keywords and summarizing CT simulation orders, suggesting that LLMs have great potential to assist in this task, reduce the workload of CT simulation therapists and improve radiation oncology workflow efficiency.
Genetic haplotypes in VWA8, OSBPL6, and ADAMTS9-AS2 are associated with immune-related adverse effects in ICI-treated patients with cancer
Raj, Prithvi , Liu, Jialiang , Zhu, Chengsong , Arana, Carlos , Mu-Mosley, Hong , Switzer, Benjamin , Daniels, Gregory A. , Shaheen, Montaser , Switzer, Benjamin , Puzanov, Igor , Zakharia, Yousef , Gerber, David E , Fattah, Farjana Jahan , Park, Jason Y. , Itzstein, Mitchell S. von , Wakeland, Edward K. , Puzanov, Igor , Xie, Yang , SoRelle, Jeffrey A. , Gerber, David E.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 28, 2025 | Volume: 13 | Issue: 10 | Pages: e012012

10.1136/jitc-2025-012012 | PMID 41151836 Get It

Background Immune-related adverse events (irAEs) remain largely unpredictable, potentially affecting multiple organ systems and occurring at almost any point during and even occasionally after immune checkpoint inhibitor (ICI) treatment. To identify populations at risk for these immune-mediated toxicities, we analyzed genetic characteristics and immune markers associated with clinically significant irAEs. Methods We carried out a genome-wide association study on 373 white patients receiving ICI treatment. We identified single nucleotide polymorphisms associated with irAEs. Blood cytokine profiling and peripheral blood mononuclear cell RNA sequencing were performed at pretreatment baseline and 6–8 weeks after ICI initiation. Findings were validated in two external cohorts. Results We identified genetic haplotypes in VWA8 (Von Willebrand Factor A Domain Containing 8) , OSBPL6 (Oxysterol Binding Protein Like 6), and ADAMTS9-AS2 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 9 Antisense RNA 2) associated with grade ≥2 irAEs. Patients carrying risk haplotypes for one or more genes exhibited significantly greater rates of grade ≥2 (OR 3.02; 95% CI 1.83 to 5.02; p<0.001), grade ≥3 (OR 3.59; 95% CI 1.93 to 6.64; p<0.001), and multiple type irAE (OR 2.60; 95% CI 1.53 to 4.39; p<0.001). Serum CCL3 levels were significantly elevated in individuals carrying risk haplotypes (p=0.03). Gene expression analysis demonstrated activated autoimmune and inflammatory pathways in the genetic risk group. Conclusions Novel polymorphisms in VWA8, OSBPL6, and ADAMTS9-AS2 may impact immune pathways, promote inflammation, potentiate autoimmune phenotypes, and convey risk of irAE in ICI-treated patients.
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
Cliff, Edward R. Scheffer , Pelaez, Guido D. , Wan, Fei , Iyengar, Varun , Zhou, Jihao , Chung, Kevin , Abdel-Razeq, Nayef , Allen, J. , Major, Ajay , Sharp, John , Gould, Patrick , Houshyar, Samin , Lynch, Ryan C. , Fleyshman, Michelle , Kidwell, Adam , Fenske, Timothy S. , Malakhov, Nikita , Mulvey, Erin , Nowakowski, Grzegorz S. , Torka, Pallawi , Russler‐Germain, David A. , Allen, Jessica , Epperla, Narendranath , Gould, Patrick , Cherng, Hua-Jay J , Houshyar, Samin , Wallace, Danielle S , Lynch, Ryan C , Kallam, Avyakta , Mei, Matthew , Merryman, Reid W , Fleyshman, Michelle , Rhodes, Joanna , Kidwell, Adam , Fenske, Timothy S , Malakhov, Nikita , Mulvey, Erin , Watkins, Marcus , Moustafa, Muhamad Alhaj , Hilal, Talal , Nowakowski, Grzegorz S , Wang, Yucai , Torka, Pallawi , Russler-Germain, David A , Major, Ajay , Sharp, John , Zhou, Jihao , Epperla, Narendranath , Cherng, Hua‐Jay J. , Wallace, Danielle , Kallam, Avyakta , Mei, Matthew , Merryman, Reid W. , Rhodes, Joanna , Watkins, Marcus P. , Moustafa, Muhamad Alhaj , Hilal, Talal , Wang, Yucai

Mayo Clinic

Clinical Cancer Research | October 27, 2025 | Volume: 32 | Issue: 1 | Pages: 159-168

10.1158/1078-0432.ccr-25-2392 | PMID 41143601 Get It

Abstract Purpose: Polatuzumab vedotin (polatuzumab) was approved for up-front treatment of diffuse large B-cell lymphoma in combination with chemoimmunotherapy (Pola-R-CHP) based on the POLARIX trial. However, when stratified by cell of origin (COO), polatuzumab seems to have greater efficacy in activated B-cell than germinal center B-cell (GCB) subtype disease. Most studies of polatuzumab used RNA expression to assess COO, whereas in routine clinical practice, the immunohistochemistry-based Hans algorithm is used. Experimental Design: To assess the impact of COO by immunohistochemistry on polatuzumab efficacy, we conducted a multicenter real-world study of adults with large B-cell lymphoma (LBCL) receiving polatuzumab from 2015 to 2024, split by receipt of polatuzumab in first-line versus relapsed/refractory settings. The primary endpoint was overall response rate (ORR) to polatuzumab-based treatment in GCB versus non-GCB relapsed/refractory LBCL. Results: Of 740 patients, 305 received polatuzumab in the first-line setting and 435 in the relapsed/refractory setting. In the relapsed/refractory cohort, the ORR in non-GCB versus GCB LBCL was 59.7% versus 36.3% [OR, 2.6; 95% confidence interval (CI), 1.77–3.84; P &lt; 0.0001], with a complete response rate of 35.7% versus 17.7% (OR, 2.6; 95% CI, 1.66–4.02; P &lt; 0.0001). Progression-free survival was longer for patients with non-GCB versus GCB COO (HR, 0.64; 95% CI, 0.5–0.83; P = 0.0006). In the first-line cohort, ORR, complete response rate, and progression-free survival were similar in non-GCB versus GCB LBCL, as hypothesized based on outcomes in the Pola-R-CHP arm of POLARIX, suggesting that the addition of polatuzumab overcomes the adverse risk of non-GCB COO in patients receiving R-CHOP. Conclusions: Based on these data, COO classification by the Hans algorithm is a strong predictor of polatuzumab efficacy in LBCL, informing real-world treatment decisions.
Assessing Critical Care Delivery Using National-Level ICU Registry Data
Kasotakis, George , Kuriyama, Akira , Smalls, Norma, Connor, Kathryn , Miller, Andrew G , Bittner, Edward A. , Temsah, Mohamad-Hani, Siddiqui, Shahla , Biswas, Saptarshi , Slain, Katherine , Akuamoah-Boateng, Kwame , Sakhuja, Ankit , Boomer, Laura A., Setliff, Erika L., Neyra, Javier A. , Rincon, Teresa , Bose, Somnath , Barwise, Amelia , Group, the Society of Critical Care Medicine (SCCM) U.S. ICU Registry Working, Barwise, Amelia K , Dempsey, Timothy , Jaehne, Anja Kathrin , Temsah, Mohamad‐Hani , Bell, Carolyn M. , Khanna, Ashish K. , Owusu, Kent A. , Alexander, Peta , Dugar, Siddharth , Cantrell, Sarah E. , Shein, Steven L. , Group, the Society of Critical Care Medicine (SCCM) U.S. ICU Registry Working

Mayo Clinic

Critical Care Medicine | October 27, 2025 | Volume: 53 | Issue: 12 | Pages: e2674-e2685

10.1097/ccm.0000000000006886 | PMID 41139471 Get It

Objective: The specialty of critical care in the United States currently lacks a single, broad, unified database. We conducted a scoping review of existing established national ICU databases, describing national and international patterns of critical care delivery. Data Sources: A systematic literature search was undertaken using MEDLINE, Embase, and Web of Science search engines. Study Selection: Projects describing national critical care delivery (including any subspecialty) published in any language were included. Titles, abstracts, and full-text manuscripts were reviewed in duplicate for inclusion. Data Extraction: National database characteristics were collected, including the number and subspecialty of ICUs, the inaugural year, data entry methodology, the number of episodes of care included, and captured clinical data elements. Data Synthesis: Of 24,003 abstracts screened, 185 manuscripts were eligible for inclusion. Thirty countries were identified as having established national ICU registries: Argentina, Australia/New Zealand, Austria, Belgium, Brazil, Canada, Denmark, Ecuador, Finland, Germany, Iceland, India, Ireland, Italy, Japan, Kenya, Malaysia, Mexico, Nepal, Netherlands, Norway, Pakistan, Paraguay, Spain, Sri Lanka, Sweden, Switzerland, United Kingdom, United States and Uruguay. Data entry commonly incorporates a combination of automated data abstraction from electronic healthcare systems and manual data entry, followed by independent validation. Frequently recorded variables include patient demographics; admission vital signs and laboratory data; comorbidities; admission source and diagnoses; ICU diagnoses, treatments, and complications; illness severity scores; and clinically relevant outcomes including discharge disposition, functional status, lengths of stay, and mortality. Conclusions: Insights and experience gained from the study of mature national ICU registries may be used to guide an equivalent U.S. multidisciplinary program aimed at benchmarking, needs assessment, quality improvement, and research facilitation
The SER-IV Pivot: MCS and LTS Increases on Computed Tomography Are Correlated to External Rotation of the Talus
Caudle, Krysta, Herbel, Cole , Lopez, Ramiro , Shi, Glenn G G, Herbel, Cole , T Haupt, Edward, Lopez, Ramiro , Kumar, Jayanth, Haupt, Edward T.

Mayo Clinic

Foot & Ankle Specialist | October 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/19386400251382281 | PMID 41139278 Get It

Background Supination-external rotation (SER) variant ankle fractures can have unstable injury patterns indicating surgical treatment. Medial clear space (MCS) on 2-dimensional radiographs is often variable, and validity of this measurement is argued. Recently, lateral talar subluxation (LTS) has been posed to be a more specific measurement than MCS likely because the pattern of injury is an external rotation pivoting displacement mechanism. However, there have been no studies using computed tomography (CT) scans to investigate the 3-dimensional talar displacement with this novel measurement. This axial rotation measurement of the talus may be a better measure than current standards, as the rotational component of these ankle fractures is underestimated. Methods This study is a retrospective review that initially identified 158 patients with unstable (SER IV) bi- or trimalleolar ankle fracture variants with injury radiographs and CT scans over a consecutive 10-year period from 2013 to 2023. Standardized measurements of radiographic MCS and LTS were acquired as well as CT scan measurements of the axial MCS, axial LTS, and a novel measurement of axial rotation angle, which is the amount of talar rotatory fracture deformity relative to the tibia. Coronal MCS and coronal LTS were also measured (Figure 1). Ultimately, 20 patients fit our inclusion criteria. The primary outcome measure investigated was the degree of external rotation of the talus in SER IV patterns. Secondary outcomes were other measurement surrogates and their correlations. Regression analysis was performed to predict the amount of rotational displacement by MCS or LTS abnormalities. Post hoc power analysis was subsequently performed. Results The mean axial rotation angle was noted to be 6.20 ± 3.79 degrees in external rotation. Axial MCS and axial LTS were 3.64 mm ± 1.10 mm and 2.20 mm ± 1.41 mm, respectively. Coronal MCS and coronal LTS were 3.15 mm ± 1.28 mm and 1.08 mm ± 1.61 mm, respectively. There were significant correlations between both MCS and LTS with respect to talar external rotation on axial CT (r = 0.85 and 0.78, respectively). Regression analysis predicted that for each 1 mm of MCS increase, there are 1.5 degrees of increased talar external rotational displacement. Similarly, for every 1 mm LTS increase, there are 2 degrees of talar external rotational displacement. Conclusion Lateral talar subluxation has previously been described as a useful measurement tool in identifying ankle instability and the potential need for surgical intervention. However, plain radiographs have limitations as the talus undergoes displacement in 3-dimensional positional planes. Using CT imaging, we found that both increased MCS and increased LTS positively correlated with increased talar external rotational as well as other displacement surrogates. There may be unrecognized rotational displacement that persists after SER ankle fracture injury, and careful consideration should be given by the surgeon for this phenomenon. Level of Evidence: Level III, retrospective cohort study
Impaired Perfusion and Early Ischemic Stroke Recurrence in Symptomatic Intracranial Atherosclerosis: BIORISK ICAS Study
Yaghi, Shadi , Khan, Farhan , Lewis, Skylar, Stipanovich, Ava, Choi, Richard , Baker, Richard, Kasab, Sami Al , Qdais, Ahmad Abu, Yaddanapudi, Sridhara , Sultana, Sabiha , Khan, Muhib , Malik, Maarij , Klaas, James P. , Bakradze, Ekaterina , Ressler, Hadley W. , McCullough‐Hicks, Margy , Cooper, Dawson C , Pillai, Abhiram Parameswaran, Hariharan, Praveen , Alam, Shaista , Mayer, Morgan, Kugler, Irina, Almiri, William , Secchi, Thaís , Mantovani, Gabriel Paulo , Rothstein, Aaron , Krishnaiah, Balaji , Alfred, Linda Sherine , Vishnu, Venugopalan Y. , Chandu, Meena, Agarwal, Ayush , Marrone, Nicola , Vozzi, Stefano, Ghannam, Malik , Elshikh, Mohamed , Hou, Yan , Peshwe, Krithika Umesh, Tunguturi, Ajay, Frontera, Jennifer , Zaidat, Osama O. , Barakat, Benan , Khan, Niha, Sen, Shayak, Coelho, Mariana Lima , Sousa, João André , Sousa, Diana Aguiar de , Soares, Mafalda , Rodrigues, Amanda Cyntia Lima Fonseca , Jhaveri, Aditya , Bhati, S., Vassilopoulou, Sofia , Tountopoulou, Argyro , Muddasani, Varsha , Henninger, Nils , Tran, Hieu , Helenius, Johanna, Khasawneh, Mohammad W , Vellimana, Ananth K. , Apfel, Ryan , Molaie, Amir , Mannino, Marina , Terruso, Valeria, Halabi, Tarek El , Reda, Mahasen , Tamer, Christel, Shu, Liqi , Khatri, Pooja , Furie, Karen L. , Liebeskind, David S. , Al Kasab, Sami , Klaas, James P , Aemaz Ur Rehman, Muhammad , Leon Guerrero, Christopher R , Ressler, Hadley Walsh , Saleh Velez, Faddi , Owens, Cameron , McCullough-Hicks, Margy , Cooper, Dawson , Parameswaran Pillai, Abhiram , Hariharan, Praveen , Heldner, Mirjam R , Antonenko, Kateryna , Almiri, William , Martins, Sheila , Mantovani, Gabriel , Rothstein, Aaron , Sloane, Kelly L , Krishnaiah, Balaji , Elangovan, Cheran , Vishnu, Venugopalan Y , Chandu, Meena , Agarwal, Ayush , Romoli, Michele , Ghannam, Malik , Elshikh, Mohamed , Dibas, Mahmoud , Hou, Yan , Tunguturi, Ajay , Marto, João Pedro , Duarte Armindo, Rui , Frontera, Jennifer , Kuohn, Lindsey , Almajali, Mohammad , Zaidat, Osama O , Barakat, Benan , Simpkins, Alexis N , Coelho, Mariana , Sargento-Freitas, Joao , Sousa, Joao Andre , Aguiar de Sousa, Diana , Soares, Mafalda , Cyntia Lima Fonseca Rodrigues, Amanda , Jhaveri, Aditya , Morsi, Rami Z , Siegler, James E , Aziz, Yasmin , Harker, Pablo , Vassilopoulou, Sofia , Tountopoulou, Argyro , de Havenon, Adam H , Henninger, Nils , Tran, Hieu , Khasawneh, Mohammad , Vellimana, Ananth , Apfel, Ryan , Molaie, Amir , Mannino, Marina , Terruso, Valeria , Klein, Piers , Shu, Liqi , Khatri, Pooja , Furie, Karen L , Nguyen, Thanh N , Liebeskind, David S. , Prabhakaran, Shyam , Yaghi, Shadi , Choi, Richard , Khan, Farhan , Sultana, Sabiha, Rehman, Muhammad Aemaz Ur , Velez, Faddi G. Saleh , Pinto, Camila Bonin , Alam, Shaista, Mayer, Morgan, Heldner, Mirjam R. , Kugler, Irina, Elangovan, Cheran , Dibas, Mahmoud , Marto, João Pedro , Kuohn, Lindsey , Almajali, Mohammad , Khan, Niha, Simpkins, Alexis N. , Sen, Shayak, Morsi, Rami Z. , Siegler, James E. , Aziz, Yasmin , Harker, Pablo , Bhati, Sonia, Havenon, Adam de , Tamer, Christel, Klein, Piers , Nguyen, Thanh N. , Prabhakaran, Shyam

Mayo Clinic

Stroke | October 23, 2025 | Volume: 57 | Issue: 1 | Pages: 96-106

10.1161/strokeaha.125.053160 | PMID 41128719 Get It

BACKGROUND: Intracranial atherosclerosis (ICAS) is associated with an increased risk of early recurrent ischemic stroke. We evaluated whether biomarkers of impaired distal perfusion—specifically, anterior circulation borderzone infarct, and hypoperfusion mismatch volume—were associated with recurrent ischemic stroke within 90 days. METHODS: The BIORISK ICAS (Biomarkers and Recurrence Risk in Symptomatic Intracranial Atherosclerosis) is a multicenter retrospective international study (35 sites) that included hospitalized patients with symptomatic ICAS (50%–99% luminal stenosis of the intracranial vertebral, basilar, distal internal carotid, or proximal middle cerebral artery) from January 2019 to June 2024. The primary outcome was recurrent ischemic stroke in the territory of the symptomatic artery within 90 days. In the primary analysis, the exposure was an acute anterior circulation borderzone infarct. In secondary analysis of the subset with presentation within 72 hours of last known normal and perfusion imaging completed, the exposure of interest was prespecified as hypoperfusion mismatch volume at T max (time to maximum) threshold of 6 seconds, dichotomized at the Youden index. We performed multivariable Cox regression to test associations between exposure variables and the outcome, adjusting for clinically relevant variables and those associated with the outcome ( P <0.1). RESULTS: Of 2050 patients with symptomatic ICAS, 1737 (84.7%) presented within 72 hours of symptom onset, among whom 509 (29.3%) underwent perfusion imaging. The primary analysis included 1891 patients; 174 (9.2%) patients had recurrent ischemic stroke in the symptomatic arterial territory. In adjusted Cox regression models, there was an association between anterior circulation borderzone infarct and recurrent ischemic stroke at 90 days (adjusted hazard ratio, 1.40 [95% CI, 1.02–1.93]). In the perfusion imaging analysis, hypoperfusion mismatch of ≥10 mL was associated with recurrent ischemic stroke (adjusted hazard ratio, 1.83 [95% CI, 1.03–3.28]). CONCLUSIONS: Biomarkers of impaired distal perfusion, anterior circulation borderzone infarct, and hypoperfusion mismatch were associated with increased risk of recurrent ischemic stroke. These findings support the use of perfusion imaging in ICAS as well as future trials investigating early reperfusion in high-risk patients with ICAS.
Factors Associated With Preference for Long-Acting Injectable Versus Daily Oral Antiretroviral Therapy Among People With HIV: Findings From the SELIGO Study
Castonguay, Breana Uhrig, Gonzalez, Humberto Rodriguez, Kh, Mayer, Fleming, Julia, Peretti, Matteo, Cachay, Edward R. , Bamford, Laura , Agans, Robert , Cole, Stephen R. , Wohl, David A. , Cachay, Edward, Kerrigan, Deanna L. , Ruíz, Carolina , Gonzalez, Humberto Rodriguez, Fleming, Julia, Peretti, Matteo , Barrington, Clare

Mayo Clinic

JAIDS Journal of Acquired Immune Deficiency Syndromes | October 23, 2025 | Volume: 101 | Issue: 2 | Pages: 183-190

10.1097/qai.0000000000003781 | PMID 41128493 Get It

Background: HIV outcomes in people with HIV (PWH) are suboptimal and inequitably distributed in the United States. Long-acting injectable antiretroviral therapy (LAI-ART) has potential to make important contributions to improving HIV outcomes and quality of life for PWH. Methods: The SELIGO Study used a 1-time, 20-minute survey of 801 PWH from the Center for AIDS Research Network of Integrated Clinical Systems cohort in 3 US cities (Boston, MA; Chapel Hill, NC; San Diego, CA) that included 54 items. Using multinomial and binary logistic regression, we assessed factors associated with LAI-ART versus daily oral ART preferences. Results: Most participants were cisgender men (82.3%); 57.0% identified as racial and/or ethnic minorities; mean years of age, 52.2; mean years living with HIV, 18.1; 2.8% were using LAI-ART. Compared with daily oral ART, 56.9% preferred LAI-ART administered monthly, and 68.0% preferred LAI-ART administered every 2 months. Factors associated with greater odds of LAI-ART preference included medication/contraception injection experience, pill burden, no medication other than ART, 4 or more clinic visits per year, detectable viral load, reporting a higher number of HIV treatment considerations, and identifying as Black. Factors associated with decreased odds of LAI-ART preference included older age, identifying as neither gay nor straight, living > 1 hour from the clinic, and considerable/extreme needle fear. Conclusions: Findings demonstrate that although there is considerable interest in LAI-ART, HIV treatment modality preferences are multifaceted. Shared decision making can ensure that conversations about ART options consistently address specific factors across diverse groups to facilitate equitable LAI-ART uptake.
OR10-08 A Retrospective, Cross-Sectional Study Reporting Contemporary Osteoporosis Treatment Patterns Before and After Anabolic Therapies
DeSapri, Kristi Tough, Denning, Shawn, Harris, Steven T. , Chiodo, Joseph , Lewiecki, Edward Michael , Denning, Shawn, Sfeir, Jad , Wang, Yamei , Cosman, Felicia

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.562 Get It

Abstract Disclosure: E.M. Lewiecki: Amgen Inc, Radius Health, Inc. K. Tough DeSapri: Amgen Inc, Radius Health, Inc. S. Denning: Amgen Inc, Radius Health, Inc. S.T. Harris: Amgen Inc, Radius Health, Inc. J.G. Sfeir: None. Y. Wang: Radius Health, Inc. J.A. Chiodo: Radius Health, Inc. F. Cosman: Amgen Inc, Biocon, Curateq, Enterabio, Radius Health, Inc, Theramex, UCB. Objectives: Studies have shown that the sequence of osteoporosis (OP) treatment can affect clinical outcome measures and likelihood of attaining therapeutic targets. The aim of this descriptive study was to evaluate the long-term OP treatment patterns in US patients prescribed anabolic therapies (ie, abaloparatide [ABL], teriparatide [TPTD], romosozumab [ROMO]). Methods: Anonymized patient claims data from a subset of ICON’s Symphony Health Patient Source Integrated Dataverse database was utilized. Men and women, aged ≥50 years with at least one prescription claim for ABL, TPTD, or ROMO from May 1, 2019 to April 30, 2021 were included. The index date was the date of the first anabolic treatment claim. For study inclusion, patients were required to have medical and pharmacy record information from 5 years prior to the start of, and 1 year after discontinuation of, anabolic treatment. Patients with a history of anabolic therapy in the 5 years prior to the index date were excluded. Results: 42,400 patients (ABL, n=16,673; TPTD, n=19,575; ROMO, n=6152) were included, of which 80%–90% were women. Persistence rates were low for all anabolic therapies. Overall mean (standard deviation [SD]) duration was 6.5 (5.8), 6.2 (5.6), and 6.0 (4.5) months for the ABL, TPTD, and ROMO groups, respectively, with approximately 45% of patients in the ABL and TPTD groups and 40% of patients in the ROMO group receiving therapy for ≤3 months. Only 18% (ABL) and 17% (TPTD) of patients received over 12 months of anabolic treatment, and 27% of patients in the ROMO group received over 9 months of treatment. In the 5 years prior to anabolic therapy, 35% (ABL), 34% (TPTD), and 47% (ROMO) of patients had prior OP treatment, with the majority having received an oral bisphosphonate (ABL, 26%; TPTD, 25%; ROMO, 21%) for a mean (SD) treatment duration of 15.8 (13.7), 15.5 (13.3), and 16.6 (14.4) months, respectively. The second most prescribed prior therapy was denosumab (ABL, 7%; TPTD, 7%; ROMO, 24%). In the 12 months after anabolic therapy, only 21% of patients in the ABL and TPTD groups received subsequent OP medication, the majority with either denosumab (9%) or oral BP (9%), and 49% of patients treated with ROMO received subsequent treatment, most of which was with denosumab (36%). Conclusions: The pattern of prescriptions of anabolic therapy in US adults identifies significant gaps in the treatment of skeletal fragility. Despite current clinical practice guidelines, the mean duration of anabolic treatment was less than 7 months, and a large majority of patients did not receive subsequent OP prescription following anabolic therapy. Additional research is needed to understand and overcome the obstacles in applying standard of care practices. Further analyses will reveal the clinical outcomes of these treatment patterns. Presentation: Saturday, July 12, 2025
MON-804 Cracks in the Foundation: Temporal and Geographic Trends in Bone Disorder Mortality in the U.S.
Kakakhel, Mian Zahid Jan , Cheema, Shamikha , Haider, Rabbia, Noor, Rizwana, L, Snehasis Jana Omprakash, Irshad, Sara Muhammad, Ullah, Aman , Jawad, Hamna , Nawaz, Ayeza, Khawar, Muneeb , Qadeer, Abdul , Ahmad, Husnain , Alcaraz, Renato, N.L, Swathi, Nawaz, Ayeza, Ahmed, Faizan

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.546 Get It

Abstract Disclosure: M. Kakakhel: None. S. Cheema: None. R. Haider: None. R. Noor: None. S. N.l: None. S.M. Irshad: None. A. Ullah: None. H. Jawad: None. A. Nawaz: None. M. Khawar: None. A. Qadeer: None. H. Ahmad: None. R. Alcaraz: None. F. Ahmed: None. Background: Bone density and structure-related disorders, such as osteoporosis and related fractures, significantly contribute to morbidity and mortality, particularly among aging populations. Monitoring temporal trends and geographic variations in mortality is essential to inform targeted public health interventions. In this study, we aimed to examine temporal and geographic variations in mortality associated with bone density and structure-related disorders in the United States from 1999 to 2022. Methods: Using ICD-10 codes M80-M85, this retrospective ecological study utilized mortality data extracted from the CDC WONDER database for the years 1999-2022. Age-adjusted mortality rates (AAMRs) were calculated and stratified by demographic variables (age, sex, and race/ethnicity) and geographic regions. Temporal trends were analyzed using Joinpoint regression to estimate annual percent changes (APCs). Geographic variations were visualized using choropleth maps, and subgroup analyses were performed to explore disparities. Statistical significance was set at p &lt; 0.05. Results: Age-adjusted mortality rates (AAMRs) for bone density and structure-related disorders decreased overall from 1999 to 2019, with a subsequent rise observed in 2020 and 2022. Joinpoint regression revealed a significant negative trend from 2007-2016 (APC = -7.46%, p &lt; 0.000001), followed by a positive reversal from 2019-2022 (APC = 3.78%, p = 0.013). Both males and females experienced declines in mortality, but females had a slightly higher APC of -3.10% compared to -2.82% for males. Asian/Pacific Islander groups exhibited the most pronounced decrease in mortality (APC = -11.92%, p &lt; 0.000001) from 2009-2015, with a positive rebound in recent years. Black or African American populations had the smallest decline (APC = -1.35%). The Southern U.S. experienced the steepest decline in mortality from 2010-2016 (APC = -10.92%, p &lt; 0.000001), followed by a strong positive trend from 2019-2022 (APC = 6.61%, p &lt; 0.000001). Conversely, the West and Northeast regions showed milder trends with less pronounced reversals. Older age groups (65-74, 75-84) showed significant decreases in mortality, particularly the 65-74 group, which reversed to a positive trend (APC = 6.97%) from 2019-2022. The highest number of deaths occurred at the decedent’s home (3,330 in 2022). Subgroup analyses indicated significant temporal shifts in the mortality patterns across different racial/ethnic groups and geographic regions. Hispanic/Latino and Asian/Pacific Islander populations exhibited an increase in mortality rates post-2019, particularly in 2020. Conclusion: From 1999 to 2022, mortality from bone density and structure-related disorders in the U.S. exhibited significant temporal and geographic variations. These findings highlight the need for targeted public health strategies. Presentation: Monday, July 14, 2025